DexCom, Inc. Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $5B+23.2% YoYTTM through 30 Jun 2026
Net Income $999.7M+73.5% YoYTTM through 30 Jun 2026
Free Cash Flow $1.4BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 60.1% |
| EBITDA Margin | 28.2% |
| Operating Margin | 19.6% |
| Net Margin | 20.1% |
Returns
30.5%ROE
13.2%ROA
22.1%ROIC
Balance Sheet Health
Debt / Equity0.47x
Current Ratio1.95x
Net Debt-$618.7Mnet cash position
Cash & Equivalents$1.1B
Quality Metrics
Altman Z-Score7.59
Piotroski F-Score7 / 9
FCF Margin28.3%
Rule of 4033.5
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $4.7B
Diluted EPS$2.53TTMFY2025: $2.09
Dividend
No dividend
Capital Allocation
R&D Spend$604M
Capex Intensity6.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| United States | $3.3B | +15.0% | |
| International | $1.3B | +16.0% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.